Acute leukemias IV: prognostic factors and treatment strategies
This 4th of a series of volumes again provides the state of the art in characterization and treatment of acute leukemias. The therapeutic progress is reflected by updates from major prospective clinical studies. The role of chemotherapy modi- fications and of bone marrow transplantation is elucidated and compared. Among prognostic factors the Philadelphia chromosome and bcr-abl gene rearrangement emerged as the most powerful risk factor in acute lymphoblastic leukemia. Molecularas well as immunologic leukemic cell markers open ways to monitor residual leukemia in clinical remission. Differentiation induction by retinoids represent a novel therapeutic principal as does the modulatioon of chemothera- py by hematopoietic growth factors. The new antileukemic ap- proaches are supported by more effective anti-infectious strategies. Data from clinical and laboratory research are presented in tables and illustrations. Up to date comprehensive overview of the large field of acu- te leukemia research and management.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Observations by a Marrow
Two Subtypes of TherapyRelated Leukemia Experience from
In Situ Amplification of Rearranged Gene Sequences in Individual
6 other sections not shown
Other editions - View all
Acute Leukemias IV: Prognostic Factors and Treatment Strategies, Volume 4
No preview available - 1994
achieved activity acute leukemia acute lymphoblastic leukemia acute myelogenous leukemia acute myeloid leukemia adult allogeneic allogeneic bone marrow amphotericin analysis ANLL antigens Ara-C Ara-CTP assay Berlin Heidelberg 1994 blast cells Blood bone marrow transplantation Cancer chemotherapy childhood acute lymphoblastic chromosome Clin Oncol clinical combination compared complete remission consolidation cyclophosphamide cytogenetic cytosine arabinoside cytotoxic daunorubicin detected diagnosis disease drug duration effect etoposide evaluated gene GM-CSF granulocyte Haematol hematological hematopoietic Hiddemann high dose high-dose human immunophenotype increased induction therapy infections infusion intensive karyotype leukemic cells lymphocytes lymphoma malignant marrow grafting median methotrexate Mitoxantrone months myelodysplastic syndromes normal patients received patients with acute Pediatric pharmacokinetic phase plasma polymerase Prognostic Factors Biichner protocol randomized rearrangement refractory regimen relapse resistance response samples significant Springer-Verlag Berlin Heidelberg T-cell Table tion toxicity treated treatment trial tumor vincristine vitro